ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1672 • ACR Convergence 2020

    Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients

    Najla Aljaberi1, Arjun Mathur2, Steffy Jose3, Theresa Hennard4, Angela Merritt1, Qing Ma5, James Rose5, Rashmi Sahay6, Chunyan Liu6, Scott Wenderfer7 and Hermine I Brunner8, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 3Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, 6Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 7Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 8PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Renal involvement in childhood-onset systemic lupus erythematosus (cSLE) is a major cause of morbidity and mortality. Current tools to identify lupus nephritis (LN) fall…
  • Abstract Number: 1816 • ACR Convergence 2020

    Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis

    Brianna Lally1, Shudan Wang2, Sammy Chalmers3, Wenzhu Mowrey3, Tamar Rubinstein4, Beatrice Goilav5 and Anna Broder6, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, New York, NY, 3Albert Einstein College of Medicine, Bronx, 4Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, 5The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 6Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

    Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…
  • Abstract Number: 0316 • ACR Convergence 2020

    High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis

    Siba Raychaudhuri1, Yasser Abdelhafez2, Soumajyoti Sarkar3, Smriti Raychaudhuri4 and Abhijit Chaudhari2, 1Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, 2University of California, Davis, Sacramento, CA, 3University of California, Davis, Davis, 4VA Sacramento Medical Center, Davis, CA

    Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis…
  • Abstract Number: 0691 • ACR Convergence 2020

    Denosumab Did Not Improve Computerized Tomography Erosion Scores When Added to Intensive Urate-Lowering Therapy in Gout: Results from a Pilot Study

    Angelo Gaffo1, Kenneth Saag2, Anthony Doyle3, Joshua Melnick4, Anne Horne5, Jeffrey Foster1, Amy Mudano1, Stephanie Biggers1, David Redden1 and Nicola Dalbeth6, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 3University of Auckland, Grafton, Auckland, New Zealand, 4University of Alabama at Birmingham (UAB), Vestavia Hills, AL, 5The University of Auckland, Auckland, New Zealand, 6University of Auckland, Auckland, New Zealand

    Background/Purpose: Bone erosion is a common complication of tophaceous gout. Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion.  We sought…
  • Abstract Number: 0789 • ACR Convergence 2020

    Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients

    Xiarepati Tieliwaerdi1, Nozima Aripova1, Michael Duryee1, Xiaoting Jiang1, Lynell Klassen2, James O'Dell1, Bryant England1, Daniel Anderson1, Ted Mikuls1 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Univerisity of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
  • Abstract Number: 1170 • ACR Convergence 2020

    Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study

    Natalia Vasquez-Canizares1, Beamon Agarwal2, Tamar Rubinstein3, Dawn Wahezi1 and Morayma Reyes-Gil1, 1Albert Einstein College of Medicine, Bronx, NY, 2GenomeRxUS LLC, Clifton Heights, PA, 3Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY

    Background/Purpose: Juvenile Scleroderma (JScl) is a heterogenous disease characterized by autoimmunity, vasculopathy, and fibrosis. Morbidity and mortality remain high in part due to the continuing…
  • Abstract Number: 1253 • ACR Convergence 2020

    Re-evaluation of the Extent of Lymphocytic Infiltration May Improve the Diagnostic Accuracy of Lip Biopsy in Primary Sjögren’s Syndrome (pSS)

    Chiara Baldini1, Francesco Ferro1, Gianmaria Governato1, Giovanni Fulvio2, Elena Elefante3, Marta Mosca1, Stefano Bombardieri1 and Valentina Donati4, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa; Department of Medical Biotechnology, University of Siena, Pisa, Italy, 4Pathology Unit, AOUP, Pisa

    Background/Purpose: Focus score (FS) remains the key element for the histological diagnosis of pSS; nonetheless, additional parameters have been proposed for clinical trials including the…
  • Abstract Number: 1725 • ACR Convergence 2020

    An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice

    Elston He1, Pratyusha Yalamanchi2, William Arnold3 and Erin Arnold4, 1Synovium, Inc., Philadelphia, PA, 2Michigan Medicine, Ann Arbor, MI, 3Retired, Wilmette, IL, 4Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL

    Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…
  • Abstract Number: 1820 • ACR Convergence 2020

    Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity

    Margaret Markiewicz1, Dayvia Russell2 and Jim Oates1, 1Medical University of South Carolina, Charleston, SC, Charleston, SC, 2.Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the…
  • Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium

    Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis

    Dirk Foell1, Carolin Park 2, Linda Ziegler 2, Dirk Holziner 3, Kirsten Minden 4, Renato Cotti 5 and Jakob Weber 5, 1University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 2University of Muenster, Muenster, Germany, 3University of Essen, Essen, Germany, 4Berlin, Germany, 5Buehlmann Laboratories, Schoenenbuch, Switzerland

    Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
  • Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium

    Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis

    Ryan Funk1 and Mara Becker 2, 1University of Kansas, Leawood, Kansas, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill

    Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
  • Abstract Number: 055 • 2020 Pediatric Rheumatology Symposium

    Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)

    Sean Donohue 1, Angela Midgley 1, Jennifer Davies 1, Rachael Wright 1, Ian Bruce 2, Michael Beresford 1 and Christian Hedrich1, 1University of Liverpool, Liverpool, United Kingdom, 2The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3).…
  • Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis 1, Denise Pires Marafon 2, Ivan Caiello 2, Manuela Pardeo 2, Giulia Marucci 2, Emanuela Sacco 2, Giusi Prencipe 2, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
  • Abstract Number: 140 • 2020 Pediatric Rheumatology Symposium

    Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade

    Claas Hinze1, Tanja Hinze 2, Helmut Wittkowski 1, Christoph Kessel 1, Sabrina Fuehner 1 and Dirk Foell 1, 1University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 2Muenster, Nordrhein-Westfalen, Germany

    Background/Purpose: Most, but not all, patients with systemic juvenile idiopathic arthritis (systemic JIA) respond to therapy with interleukin (IL)-1 blocking agents but predictive factors have…
  • Abstract Number: 156 • 2020 Pediatric Rheumatology Symposium

    Metabolic Profiling in Juvenile Dermatomyositis

    Jeffrey Dvergsten1, Olga Ilkayeva 2, Lawrence Landerman 2, Michael Muehlbauer 3, David Pisetsky 4, Ann Reed 3 and Kim Huffman 5, 1Duke University Hospital, Hillsborough, 2Duke University, Durham, NC, 3Duke University, Durham, 4Duke University Medical Center, Durham, 5Durham

    Background/Purpose: Investigators have made significant progress piecing together pathogenic mechanisms of juvenile dermatomyositis (DM).  However, this remains an incomplete puzzle, and optimal approaches to diagnosing,…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology